Ann: Shareholder Update June Quarter 2016-OBJ.AX, page-54

They were talking about Nurofen when the talked about commercialisation, not Voltaren. I wrote it down word for word as it was being said. No offence to Viper, but it's wrong.

I'm not saying that Voltaren aren't working with OBJ on an applicator, but the Nurofen applicator is far more advanced in its development and is close to commercialisation.

They said Voltaren came to OBJ after the Bodyguard trial for "possible product development". It's in the works but probably a bit further off unless Voltaren are able to commercialise quicker than Nurofen.